Shares of BioLife Solutions (BLFS) opened at $5.14 on Friday. BioLife Solutions has a fifty-two week low of $1.95 and a fifty-two week high of $7.53. The stock has a market cap of $70.06, a PE ratio of -12.24 and a beta of 0.38.
BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, March 8th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). BioLife Solutions had a negative return on equity of 44.83% and a negative net margin of 22.82%. The firm had revenue of $3.13 million during the quarter, compared to analysts’ expectations of $3.10 million. analysts anticipate that BioLife Solutions will post -0.1 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN purchased a new stake in shares of BioLife Solutions in the fourth quarter worth about $111,000. EAM Investors LLC purchased a new stake in shares of BioLife Solutions in the third quarter worth about $555,000. Millennium Management LLC lifted its holdings in shares of BioLife Solutions by 901.6% in the fourth quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock worth $1,095,000 after buying an additional 164,324 shares in the last quarter. Granite Investment Partners LLC purchased a new stake in shares of BioLife Solutions in the third quarter worth about $1,205,000. Finally, Essex Investment Management Co. LLC raised its stake in BioLife Solutions by 199.8% in the fourth quarter. Essex Investment Management Co. LLC now owns 254,096 shares of the medical equipment provider’s stock valued at $1,525,000 after purchasing an additional 169,341 shares in the last quarter. 12.19% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3258726/biolife-solutions-blfs-given-a-8-00-price-target-by-maxim-group-analysts.html.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.